Sanofi | SNY - Operating Expenses




Sanofi reported EUR10.52B in Operating Expenses for its fiscal quarter ending in September of 2024.

Operating Expenses Change Date
AbbVie USD 16.59B 6.05B Dec/2024
Amgen USD 6.78B 752M Dec/2024
AstraZeneca USD 12.86B 2.06B Dec/2024
Bristol-Myers Squibb USD 12.17B 4.98B Dec/2024
Canopy Growth CAD 108.61M 21.09M Sep/2024
Corcept Therapeutics USD 135.95M 7.74M Sep/2024
Drreddys Laboratories INR 62.61B 3.81B Sep/2024
Eli Lilly USD 8.38B 1.38B Dec/2024
Galapagos EUR 138.22M 24.07M Dec/2024
Genmab DKK 4.25B 812M Dec/2024
GlaxoSmithKline GBP 7.42B 402M Dec/2024
Glaxosmithkline GBP 7.35B 1.11B Sep/2024
Indivior 213M 218M Sep/2024
J&J USD 18.63B 500M Dec/2024
Merck USD 11.4B 1.3B Dec/2024
Novartis USD 11.28B 1.73B Dec/2024
Novartis USD 8.73B 115M Sep/2024
Pacira USD 144.86M 2.19M Sep/2024
Perrigo USD 1.01B 8.3M Sep/2024
Pfizer USD 18.17B 5.76B Dec/2024
Prestige Brands USD 69.09M 3.96M Dec/2024
Roche Holding CHF 11.43B 1.48B Dec/2024
Sanofi EUR 10.07B 969M Sep/2024
Sanofi EUR 10.52B 1.42B Sep/2024
Supernus Pharmaceuticals USD 1.01B 857.04M Sep/2024
UCB EUR 1.23B 1.31B Jun/2024
Zoetis USD 1.59B 3.65B Dec/2024